StockNews.com Initiates Coverage on Aptose Biosciences (NASDAQ:APTO)

StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO – Get Rating) (TSE:APS) in a note issued to investors on Saturday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Other analysts have also issued research reports about the company. Canaccord Genuity Group lowered their target price on Aptose Biosciences from $13.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, March 27th. Royal Bank of Canada restated an “outperform” rating and issued a $5.00 price objective on shares of Aptose Biosciences in a research report on Friday, March 24th.

Get Aptose Biosciences alerts:

Aptose Biosciences Stock Performance

Aptose Biosciences stock opened at $0.46 on Friday. The firm has a market capitalization of $42.89 million, a price-to-earnings ratio of -0.97 and a beta of 1.54. Aptose Biosciences has a fifty-two week low of $0.43 and a fifty-two week high of $1.09. The stock’s fifty day moving average is $0.54 and its two-hundred day moving average is $0.61.

Aptose Biosciences (NASDAQ:APTO – Get Rating) (TSE:APS) last posted its earnings results on Thursday, March 23rd. The biotechnology company reported ($0.11) earnings per share for the quarter, meeting the consensus estimate of ($0.11). During the same period last year, the business posted ($0.27) earnings per share. As a group, sell-side analysts forecast that Aptose Biosciences will post -0.5 EPS for the current fiscal year.

Hedge Funds Weigh In On Aptose Biosciences

Large investors have recently added to or reduced their stakes in the business. DRW Securities LLC acquired a new stake in Aptose Biosciences during the fourth quarter worth about $5,158,000. Sigma Planning Corp increased its stake in Aptose Biosciences by 34.9% during the first quarter. Sigma Planning Corp now owns 1,444,550 shares of the biotechnology company’s stock worth $925,000 after acquiring an additional 374,046 shares during the last quarter. Annandale Capital LLC increased its stake in Aptose Biosciences by 81.6% during the third quarter. Annandale Capital LLC now owns 710,000 shares of the biotechnology company’s stock worth $422,000 after acquiring an additional 319,106 shares during the last quarter. Callan Capital LLC acquired a new stake in Aptose Biosciences during the fourth quarter worth about $91,000. Finally, Carlson Capital L P increased its stake in Aptose Biosciences by 5.4% during the third quarter. Carlson Capital L P now owns 2,010,000 shares of the biotechnology company’s stock worth $1,196,000 after acquiring an additional 102,500 shares during the last quarter. 26.60% of the stock is currently owned by hedge funds and other institutional investors.

Aptose Biosciences Company Profile

(Get Rating)

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

See Also

• Get a free copy of the StockNews.com research report on Aptose Biosciences (APTO)
• Applied Materials: Cracks In The Chip Recovery Or Time To Buy? 
• Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
• How Many Roth IRAs Can You Have?
• Why You Should Consider Buying Nvidia Ahead Of Earnings
• Foot Locker And The Ebbing Tide Of Discretionary Spending 

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.